Towards Healthcare
Oncolytic Virus CDMO Services Market Trends and Companies

Oncolytic Virus CDMO Services Market Transforming Biotech 2025

Rising cancer prevalence globally, increasing demand for innovative therapies. North America led the global market owing to the presence of leading CDMO players and contract manufacturing facilities.

Content

  • Last Updated: 20 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The oncolytic virus CDMO services market expected to generate hundreds of millions by 2034. Learn about emerging trends, market drivers, and sector opportunities.

North America is leading the oncolytic virus CDMO services market share by 40% due to the growing demand for cancer treatments, the prevalence of cancer, and government initiatives promoting health, drive market growth.

Some key players include Catalent Inc., Lonza Group, WuXi AppTec, Brammer Bio (Thermo Fisher), Curia (formerly AMRI), Cobra Biologics, Vigene Biosciences, Oxford Biomedica, REGENXBIO, Oncolytics Biotech, and Viralgen Vector Core, among others.

Indian Cancer Society (ICS), Personalized Medicine Coalition, Government of Canada, Food and Drug Administration, clinicaltrials.gov, WHO, European Organization for Research and Treatment of Cancer (EORTC), JAMA, Cancer Patients Aid Association (CPAA), GOV.UK and MASCC, among others.
Any Questions